Radiopharm Theranostics Ltd
RADX Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- Radiopharm Theranostics Ltd had $2.8M of revenue in fiscal 2026, down 23.8% on the year before.
- Its operating margin was −2,051.5%, down 1,000.9 pts: of every 100 in sales, about −2,052 is left after running the business.
- Radiopharm Theranostics Ltd lost $57.0M in fiscal 2026.
Market cap
—
P/E
—
Revenue
$2.8M
Net income
−$57.0M
Free cash flow
—
Operating margin
−2,051.5%
Radiopharm Theranostics Ltd in 30 seconds · fiscal 2026
Are sales growing?
−23.8%
No. Sales fell 23.8% last year.
Does it make a profit?
−2,057.5%
No. It lost money last year.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
What Radiopharm Theranostics Ltd does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 20-F · Sep 30, 2026
- Legal name
- Radiopharm Theranostics Ltd
- CIK
- 0001949257
Radiopharm Theranostics Ltd · RADX
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $0.3M | $0.3M | $3.6M | $2.8M |
| Revenue growth | — | 2.3% | 1,114.4% | −23.8% |
| Gross margin | 100.0% | 100.0% | 1.1% | 9.5% |
| Operating margin | −11,794.5% | −15,778.7% | −1,050.6% | −2,051.5% |
| Net income | −$34.6M | −$47.9M | −$38.3M | −$57.0M |
| Net margin | −11,836.9% | −16,025.8% | −1,055.3% | −2,057.5% |
| Diluted EPS | −$3,396.00 | −$3,723.00 | −$528.00 | −$537.00 |
| Cash | ||||
| Cash from operations | −$23.2M | −$23.0M | −$36.6M | −$52.8M |
| Capital expenditure | $0.0M | — | — | — |
| Free cash flow | −$23.2M | — | — | — |
| FCF margin | −7,950.4% | — | — | — |
| Share count change | — | 26.4% | 438.5% | 47.7% |
| Debt and strength | ||||
| Cash and short-term investments | $11.7M | $18.6M | $29.1M | $4.1M |
| Shareholders' equity | $45.6M | $27.4M | $42.9M | $22.3M |
| Current ratio | — | 1.3x | 2.7x | 1.2x |
| Interest coverage | −400.5x | −73.4x | −584.6x | −505.2x |
| Returns and quality | ||||
| Return on equity | −75.9% | −131.5% | −109.2% | −174.7% |
| Piotroski F-score | — | — | 4 | 3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Radiopharm Theranostics Ltd · RADX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001949257). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.